Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 878 of 6351
-
Gut bacteria may boost lung cancer therapy
Disease control Recruiting nowThis is a randomized, active-controlled, parallel-group, double-blind Phase II trial, of oral restorative microbiota therapy (RMT) or placebo combined with intravenous (IV) durvalumab (MEDI4736) plus chemotherapy in patients with treatment naïve advanced or metastatic adenocarcin…
Phase 2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 26, 2026 16:52 UTC
-
Brain radiation boost may extend cancer control in lung and melanoma patients
Disease control Recruiting nowThe primary objective of the study is to assess the efficacy in terms of CNS-specific PFS of the combination of standard systemic treatment plus SRS vs. standard systemic treatment alone in patients with newly diagnosed and untreated (except for surgery) asymptomatic or oligosymp…
Phase 3 • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Diabetes drug metformin tested as new weapon against kidney disease
Disease control Recruiting nowThis study will investigate if a medication (metformin) widely used in the treatment of diabetes could be re-purposed for the treatment of patients with a diagnosis of early stage ADPKD to slow the rate of kidney function decline, reducing morbidity and mortality and improving th…
Phase 3 • Sponsor: The University of Queensland • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Can an extra radiation dose keep HER2+ breast cancer at bay?
Disease control Recruiting nowThe purpose of this study is to analyze treatment outcomes related to tumor bed boost of postoperative radiation therapy in patient with HER2+ breast cancer who underwent breast conserving surgery. The main questions it aims to answer are: * 7-year ipsilateral breast tumor recu…
Sponsor: Samsung Medical Center • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Brain tumor patients get Virus-Radiation combo in early trial
Disease control Recruiting nowThe primary goal of this Phase I study is to determine the maximum tolerated dose of oncolytic adenovirus mediated double suicide-gene therapy in combination with fractionated stereotactic radiosurgery in patients with recurrent high-grade astrocytoma undergoing resection.
Phase 1 • Sponsor: Henry Ford Health System • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Could a cancer drug help kids with rare brain disorder?
Disease control Recruiting nowThis study is a two periods multi-center Phase II trial, with a 6 months double-blind, placebo-controlled period followed by open label period, to assess the efficacy and safety of alpelisib (BYL719) in pediatric and adult patients with Megalencephaly-CApillary malformation Polym…
Phase 2 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New combo therapy aims to cut transfusions and boost brain health in premature infants
Disease control Recruiting nowIn this phase II trial, the investigators overarching goal is to demonstrate the feasibility and potential benefit of darbepoetin (Darbe) plus slow-release intravenous (IV) iron to decrease transfusions, maintain iron sufficiency and improve the neurodevelopmental outcomes of pre…
Phase 2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New hope for aggressive lymphoma: targeted drug combo enters trial
Disease control Recruiting nowThis study aim to evaluate the efficacy and safety of zanubrutinib combined with R-CHOP in the treatment of DLBCL patients with p53 protein expression.
Phase 2 • Sponsor: Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Triple threat: new combo targets nasopharyngeal cancer spread
Disease control OngoingThis is a multicenter, single-arm, phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of SBRT combined with programmed death 1 (PD-1) antibody and chemotherapy in nasopharyngeal carcinoma patients with oligometastasis.
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Could your own immune cells fight brain tumors? new trial tests lifileucel
Disease control OngoingThis is an open label study evaluating lifileucel (LN-144) in patients with melanoma brain metastases.
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 26, 2026 16:19 UTC
-
New hope for patients with rare brain lining cancer spread
Disease control OngoingThe objective of the present study is to determine the feasibility and to explore anti-tumor activity of intrathecal double immune checkpoint inhibition for patients with newly diagnosed leptomeningeal metastases from non-small cell lung cancer without driver mutation or melanoma…
Phase 1 • Sponsor: University of Zurich • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Can Ultra-Processed foods make you eat more? a study investigates
Knowledge-focused CompletedProtocol Number: 22DK0002 Title: Effects of Ultra-processed versus Unprocessed Diets on Energy Metabolism Background: Many diets worldwide include both processed and unprocessed foods. Researchers want to study the effects these foods have on a person s health. Objective: To…
Sponsor: National Institutes of Health Clinical Center (CC) • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Custom-Made cancer vaccine shows promise in early trial
Disease control CompletedThis clinical trial aims to evaluate the safety, immunogenicity, and preliminary efficacy of a personalized neoantigen peptide vaccine in patients with advanced cancer or at high risk of recurrence. The study is designed for patients whose tumors have specific mutations identifia…
Phase 1/2 • Sponsor: Seqker Biosciences, Inc. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Fast-MRI could spot liver cancer earlier than ultrasound alone
Diagnosis Recruiting nowIntro: Hepatocellular carcinoma (HCC) is the 6th leading cause of cancer worldwide. In France, more than 10,000 new cases are identified each year. The latter occur in 85% of cases in cirrhosis, the most frequent causes of which are excessive alcohol consumption, metabolic syndro…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Diagnosis
Last updated Jun 27, 2026 11:01 UTC
-
New drug shows promise for bulging eyes in thyroid disease
Disease control CompletedTo evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.
Phase 3 • Sponsor: Immunovant Sciences GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Water-Jet robot takes aim at prostate cancer and urinary troubles
Disease control OngoingThe goal of this clinical trial is to assess the performance and safety of the AQUABEAM Robotic System for the resection and removal of prostate tissue in patients experiencing lower urinary tract symptoms (LUTS) and are diagnosed with localized prostate cancer. Participants will…
Sponsor: PROCEPT BioRobotics • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New Ultrasound-Guided scope may slash deadly bleeding risk in liver cancer patients
Disease control Recruiting nowRebleeding rate is high in hepatocellular carcinoma (HCC) patients with variceal bleeding despite conventional endoscopic therapies for esophageal and gastric varices (EV, GV). Secondary prevention of variceal rebleeding was reported to improve outcomes of HCC patients, but the o…
Sponsor: Chinese University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New targeted drug aims to fight hard-to-treat bladder cancers
Disease control OngoingThe purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-300 in cancers with FGFR3 activating gene alterations, including locally advanced/metastatic urothelial carcinoma of the bladder and urinary tract …
Phase 1/2 • Sponsor: Tyra Biosciences, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New radiation 'Smart Bomb' targets Hard-to-Treat myeloma
Disease control Recruiting nowThis phase I trial tests the safety, side effects, and best dose of actinium Ac 225-DOTA-daratumumab (225Ac-DOTA-daratumumab) in combination with daratumumab and indium In 111-DOTA-daratumumab (111In-DOTA-daratumumab) in treating patients with multiple myeloma that does not respo…
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Promising targeted therapy for tough brain cancers moves forward
Disease control Recruiting nowThis study will evaluate the safety and efficacy of Lutathera (177Lu-DOTATATE) in patients with progressive or recurrent High-Grade Central Nervous System (CNS) tumors and meningiomas that demonstrate uptake on DOTATATE PET. The drug will be given intravenously once every 8 weeks…
Phase 1/2 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC